A KKR-led consortium has ended its pursuit of Australia-listed hospital operator Ramsay Health Care, having failed to reach an agreement on a AUD 20.1bn (USD 13.9bn) take-private that would have been among the largest private equity deals ever seen in...
Worg, a China-based drug developer, has closed a Series B round of CNY400m (USD57m) from five local investors - Jiachen Capital, Longpan Capital, Kaitai Capital, Puhua Capital and Anji Ruixing Capital.
Indian drug maker Mankind Pharma has filed for a domestic IPO, setting up an exit for Capital International, a private equity arm of Capital Group.
Australia’s Blackbird Ventures has led a AUD 35m (USD 23.4m) Series B round for Sonder, a staff and student management app focused on wellbeing and safety.
HighLight Capital, a China-based life sciences investor, has completed a first close of USD 540m on its fourth US dollar-denominated fund. The overall target is USD 650m.
Everstone Capital has acquired a controlling stake in Indian pharmaceuticals manufacturer Softgel Healthcare (SHPL) for an undisclosed sum.
Chinese online pharmacy platform Dingdang Health has raised HKD 402.4m (USD 51m) through a Hong Kong IPO, defying challenging conditions for financial sponsors targeting the bourse.
Singapore-based Docquity, a networking service for more than 300,000 doctors across Southeast Asia, has raised USD 44m in Series C funding led by Japan’s Itochu Corporation.
Chinese drug developer BoomRay Pharmaceuticals has raised a CNY300m (USD 43m) Series A round led by Sequoia Capital China.
Shanghai-based cell therapy developer Neukio Biotherapeutics has raised USD 50m in the first tranche of a Series A round led by medical technology-focused CD Capital. Other new investors include Alwin Capital and Surplus Capital.
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a USD 50m investment in MedGenome, an India-based genetic testing business.
Japan’s D Capital, a private equity firm specialising in digital transformation that spun out from Unison Capital last year, has raised JPY 26bn (USD 188m) for its debut fund against a target of JPY 30bn.
Bain Capital has agreed to acquire Evident, a Japan-based medical devices manufacturer best known for producing microscopes, from Olympus Corporation for JPY 427.7bn (USD 3.08bn).
Kedaara Capital has invested USD 50m for a significant minority stake in Oasis Fertility, a fertility treatment business with more than 26 centres across India.
Australia-listed hospital operator Ramsay Health Care has rejected an alternative buyout proposal from a KKR-led consortium after progress with the initial bid was slowed by the need to conduct due diligence on Ramsay Santé, the company’s separate...
Japan’s Ubie, a healthcare technology start-up that uses artificial intelligence (AI) for symptom-checking questionnaires, has raised USD 26.2m in Series C funding from local investors.
Korea’s Airs Medical, a healthcare technology provider active in diagnostics software and robotics, has raised USD 20m in Series B funding from Klim Ventures, Q Capital Partners, and Hanwha Life Insurance.
Three entities under China Merchants Group (CMG) have led a USD 80m Series B round for Porton Advanced Solutions, a local contract development and manufacturing organisation (CDMO) that focuses solely on gene and cell therapy services.
Ontario Teachers' Pension Plan (OTPP) has agreed its first control private equity buyout in India, taking a majority stake in Sahyadri Hospitals and setting up a partial exit for Everstone Group.
KKR has exited its entire interest in Indian hospital operator Max Healthcare Institute – nearly four years after assuming control of the business by merging it with an existing portfolio company – with proceeds of approximately INR 91.9bn (USD 1.15bn).
Healthcare is not a particularly energy-intensive industry, but specialists such as Quadria Capital are tightening up operations where possible at hospitals
The Carlyle Group has committed JPY 7bn (USD 52.2m) to CureApp, a Japan-based developer of software for use in the treatment of medical conditions, as part of the company’s Series G round.
Singapore-based healthcare specialist Quadria Capital is set for a full exit from pharmaceuticals industry supplier Concord Biotech via an India IPO.
Abu Dhabi Investment Authority (ADIA) has agreed to invest INR 6.6bn (USD 83.5m) in India’s Aditya Birla Health Insurance (ADBHI) for a 10% stake.